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Abstract
IL-36 cytokines are members of the IL-1 family of cytokines that stimulate dendritic cells and
T cells leading to enhanced T helper 1 responses in vitro and in vivo; however, their role in
host defense has not been fully addressed thus far. The objective of this study was to exam-
ine the role of IL-36R signaling in the control of mycobacterial infection, using models of sys-
temic attenuatedM. bovis BCG infection and virulent aerogenicM. tuberculosis infection.
IL-36γ expression was increased in the lung ofM. bovis BCG infected mice. However, IL-
36R deficient mice infected withM. bovis BCG showed similar survival and control of the in-
fection as compared to wild-type mice, although their lung pathology and CXCL1 response
were transiently different. While highly susceptible TNF-α deficient mice succumbed with
overwhelmingM. tuberculosis infection, and IL-1RI deficient mice showed intermediate
susceptibility, IL-36R-deficient mice controlled the infection, with bacterial burden, lung in-
flammation and pathology, similar to wild-type controls. Therefore, IL-36R signaling has
only limited influence in the control of mycobacterial infection.
Introduction
IL-36 cytokines belong to the IL-1 family of cytokines and include three agonists IL-36α, IL-
36β, and IL-36γ that bind to IL-36R leading to the recruitment of IL-1RAcP, the common co-
receptor for IL-1 and IL-33, and to activation of similar intracellular pathways as other IL-1 cy-
tokine family members [1]. IL-36 receptor antagonist (IL-36Ra) binds also to IL-36R but does
not induce any signaling and acts as a natural IL-36 inhibitor, thus sharing similar to IL-1Ra
for IL-1. We and others have recently shown that IL-36R is expressed by human and mouse
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dendritic cells (DC) and that IL-36 stimulates the production of several cytokines by DC, in-
cluding TNF-α, IL-1, IL-12, and IL-23, as well as the maturation of DC with enhanced expres-
sion of MHC class 2 and co-stimulatory molecules [2], [3], [4]. Human T cells do not express
IL-36R and fail to respond directly to IL-36 [4], [3]. However, IL-36 stimulation of human
monocyte-derived DC is able to induce the production of IFN-γ in T cell/monocyte DC alloge-
neic co-cultures, thus suggesting that IL-36 can promote Th1 responses in human cells [3]. In
contrast, IL-36R is expressed by mouse CD4+ T cells, and more specifically by naïve CD4+ T
cells. Accordingly, IL-36, but not other IL-1 family cytokines, is able to stimulate the prolifera-
tion and IL-2 release by naïve CD4+ T cells. In combination with IL-12, IL-36 markedly stimu-
lated the polarization of naïve T cells into Th1 cells in vitro [5], and intradermal injection of
IL-36 in an immunization protocol was able to induce Th1 responses in vivo [2]. Taken togeth-
er, these findings suggest that IL-36 could play a critical role in host defense against pathogens,
particularly against intracellular microorganisms controlled by Th1 responses. Consistent with
this hypothesis, we recently observed that production of IFN-γ, TNF-α, IL-6 and nitric oxide
(NO) was decreased in ex vivo stimulated splenocytes of IL-36R deficient mice infected byM.
bovis BCG as compared to wild-type mice [5].
It is generally accepted that less than 10% of individuals infected withMycobacterium tuber-
culosis will develop an active disease, suggesting that the host immune system is usually effi-
cient in the control of mycobacteria, although the infection is not cleared and can remain in a
latent form for many years [6], [7]. Immunodepression of the host can favor a reactivation of
latent tuberculosis infection. Indeed, coordinated innate and adaptive immune responses are
required for efficient control ofM. tuberculosis infection, including T cells, macrophages, and
the expression of IFN-γ, TNF-α, IL-1, IL-12, NO, reactive oxygen and reactive nitrogen inter-
mediates [8], [9], [10], [11], [12]. One of the most compelling example regarding the role of the
immune system in controllingM. tuberculosis infection is the reactivation of latent tuberculo-
sis, as well as increased susceptibility to primary tuberculosis infection in patients treated for
inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn’s disease with TNF-α
antagonists [13], [14], [15], [16]. In mice, the IL-1R1 pathway seems essential for the control of
acuteM. tuberculosis infection, and both IL-1α and IL-1β have been implicated [17], [18], [19],
[20], [21], [22], [23], [24]. We therefore addressed the contribution of IL-36 cytokines and of
the IL-36R signaling pathway in the control of mycobacterial infection by using IL-36R gene
deficient mice in two models, namelyM. bovis BCG systemic infection andM. tuberculosis
aerogenic infection. This question has potential clinical implication in the context of future
drugs targeting IL-36R signaling. Indeed, several lines of evidence indicate that IL-36 signaling
is involved in the pathogenesis of psoriasis (reviewed in [25]), thus leading to consider the de-
velopment of therapies blocking IL-36 for this indication.
The results described herein show that while both TNF-α and IL-1R1 pathways were re-
quired to controlM. tuberculosis infection, absence of functional IL-36R did not compromise
survival and bacterial clearance inM. bovis BCG andM. tuberculosis infections.
Materials and Methods
Mice
WT C57BL/6 and mice deficient for IL-36R [26], IL-1R1 [27], and TNF-α [28] were housed in
the Transgenose Institute animal facility (CNRS UPS44, Orleans). WT C57BL/6 and mice defi-
cient for IL-36R were also housed in the animal facility of the Centre Medical Universitaire,
University of Geneva. The generation of IL-36R KOmice was previously described [26]. These
mice were crossed for at least 9 generations with C57BL/6 mice. The backcross into the C57BL/
6 background was performed by using a marker-assisted selection protocol (MASP) approach,
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also termed “speed congenics” [29]. The other KO mice were backcrossed at least 7–10 times
on C57BL/6 genetic background. For infection withMycobacterium bovis BCG, adult mice (8–
12 week old) were kept in a conventional animal facility (Geneva). ForMycobacterium tubercu-
losis infection, adult (8–12 week old) animals were kept in isolators in a biohazard animal unit
(Orleans). The infected mice were monitored regularly for clinical status and weighed twice
weekly. Water and food were provided ad libitum. All animal experiments onM. bovis BCG
andM. tuberculosis were approved by the Geneva cantonal authority for animal experimenta-
tion (authorization N° 31.1.1005/3202/2) and by the Ethics Committee for Animal Experimen-
tation of CNRS Campus Orleans” (CCO; N° CLE CCO 2012–1001), respectively.
Intratracheal instillation of lipopolysaccharide (LPS)
200 μg LPS (Escherichia coli serotype O55:B5) dissolved in 50 μl sterile 0.9% NaCl was instilled
intratracheally using a canula into anesthetized mice. Control mice were instilled intratrache-
ally with 50 μl LPS-free sterile 0.9% NaCl. The mice were euthanized 6 h after instillation and
lungs collected for total RNA preparation.
Bacteria and infection
M. bovis BCG infection. Adult WT and IL-36R KOmice were infected intravenously (i.v)
with 5x106 CFU livingM. bovis BCG Pasteur strain 1173 P2 as previously described [30]. Hu-
mane endpoints were used during theM. bovis BCG infection survival study. Mice were ob-
served daily and weighed twice a week. To minimized animal distress, mice presenting signs of
distress or bodyweight loss were examined twice a day, and mice showing prostration or body
weight loss20% were euthanized by isofluorane anesthesia, exsanguination, and cervical dis-
location. Mice were sacrificed 28 or 180 days post-infection. Lung bacterial load was evaluated
by plating lung homogenates on 7H11 agar plates and counting the number of colonies.
M. tuberculosis infection. M. tuberculosisH37Rv (Pasteur) aliquots kept frozen at -80°C
were thawed, diluted in sterile saline containing 0.05% Tween 20 and clumping was disrupted
by 30 repeated aspirations through a 26 gauge needle (Omnican, Braun, Germany). Pulmonary
infection withM. tuberculosisH37Rv was performed by instillation of 1000–3000 CFU/lung
into the nasal cavities (20μl each) under xylazine-ketamine anaesthesia (100mg/kg ketamine,
10mg/kg xylazine, i.p.), and the inoculum size was verified 24 h after infection by determining
bacterial load in the lungs. Humane endpoints were used during theM.tuberculosis infection
survival studies. Mice were observed daily and weighed twice a week. To minimize animal dis-
tress, mice presenting signs of distress or bodyweight loss were examined twice a day, and mice
showing prostration or bodyweight loss>20% were euthanized by cervical dislocation. There
was no incident or unexpected mortality in the infected animals.
M. tuberculosis bacterial loads in the lung of infected mice were evaluated at different time
points after infection withM. tuberculosisH37Rv as described [31]. Organs were weighed and
defined aliquots were homogenized in PBS in a Dispomix homogenizer (Medic Tools, Axon-
lab, Baden-Daettwil, Switzerland). Tenfold serial dilutions of organ homogenates in 0.05%
Tween 20 containing 0.9% NaCl were plated in duplicates onto Middlebrook 7H11 (Difco)
agar plates containing 10% OADC and incubated at 37°C. Colonies were enumerated at 3
weeks and results are expressed as log10 CFU per organ.
Cytokine determination
Lung homogenates were centrifuged (3 min at 14,500 rpm), the supernatants sterilized by cen-
trifugation through 0.22 mm filter (3 min at 14,500 rpm; Costar-Corning, Badhoevedorp, The
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Netherlands), immediately frozen on dry ice and stored at -80°C until determination of
CXCL1 and IFNγ levels by ELISA (Duoset R&D Systems, Abingdon, UK).
RNA extraction and RT-qPCR
Total RNA was extracted from lungs ofM. bovis BCG andM. tuberculosis infected mice, as
well as after LPS challenge using TRIzol reagent, according to manufacturer’s instructions, and
further purified on RNeasy columns (Qiagen AG, Hombrechtikon, Switzerland). Total RNA
(1 μg) was reverse transcribed using SuperScript II Reverse transcriptase (Invitrogen Life Tech-
nologies). The mRNA levels for genes of interest were examined by quantitative RT-PCR using
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). Values obtained with the
SDS 2.2 (Applied Biosystems, Zug, Switzerland) were imported into Microsoft Excel for analy-
ses and gene expression was calculated using the comparative method (2–ΔCt) for relative quan-
tification by normalization to Gapdh or L32 gene expression. The primer sequences used for
real-time quantitative RT-PCR are described in Table 1.
Histopathological analysis
For histological analysis lungs fromM. bovis BCG andM. tuberculosis infected mice were fixed
in 4% phosphate buffered formalin, paraffin-embedded, and 4 μm sections (forM. bovis BCG)
and 3 μm sections (forM. tuberculosis) stained with haematoxylin and eosin and a modified
Ziehl-Neelsen method. The latter involved staining in a prewarmed (60°C) carbol-fuchsin solu-
tion for 10 min followed by destaining in 20% sulphuric acid and 90% ethanol before counter-
staining with methylene blue. Histopathological analyses were done by quantification of lung
tissue and lung free of lesions on tissue sections comprising a lung surface of 45 ± 20 mm2 corre-
sponding to one or two lobe sections per animal. Percentage of free alveolar space corresponds
to % lung lesion free /lung tissue. Scorings were determined by a pathologist using digital micro-
scopic images acquired by Mirax Digital Slide Scanner and Mirax Viewer (Carl Zeiss).
In situ hybridization study
In situ hybridization was performed at the Histo-Pathology / in situ Hybridisation Core Facility
(Faculty of Medicine, Geneva University). A DNA template for riboprobe synthesis was
Table 1. Nucleotide sequences of primers used for RT-qPCR.
Primer sequences for RTqPCR
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generated from a plasmid containing the cDNA for murine Il36g. This template was obtained
by PCR using the forward primer mmu-IL36G_SP6 (5’CCGATTTAGGTGACACTATAGA
AAACAGGAATGGCTTCATTGG 3’) and the reverse primer mmu-IL36G_T7 (5’CCGTAA
TACGACTCACTATAGGGCGAGAGAGCTGGGCTATTTG 3’). In vitro transcription was
carried out in a cocktail of 1mM rATP, rCTP, rGTP, 0.65mM rUTP, and 0.35mM digoxigenin-
UTP (RNA kit labeling from Roche), 1 ml of ribonuclease inhibitor (40 U/ml MBI Promega),
0.5 mg of DNA template, 0.5 ml of SP6 RNA polymerase (SP6: 20 U/l, New England Biolabs),
in a final volume of 20 ml. The reaction mix was incubated at 37°C for 2.5 hours followed by a
15 mn incubation with a DNase I/MgCl2 mix to remove the DNA template (1.6ml of 300 mM
MgCl2, 2 ml of DNase I [10 U/l, Roche], 16.4 l of DEPC water). RNA was ethanol precipitated
and dissolved in DEPC water to 150 ng/ml. 4um thick sections from paraffine-embedded mu-
rine tissues fixed previously in formol were applied on Superfrost slides and loaded onto the
Discovery automated slide-processing system (Ventana Medical Systems, Inc). Baking and
deparaffinization steps were performed as programmed in the protocol for the RiboMap in situ
hybridization reagent system (Ventana Medical Systems, Inc) on the instrument. In situ hy-
bridization protocol was designed based on the standard protocol described in the manufac-
ture's RiboMap application note. The first fixation step was performed using formalin-based
RiboPrep reagent for 36 minutes at 37°C. Then, the sections were acid-treated using hydro-
chloride-based RiboClear reagent for 12 minutes at 37°C. Slides were then processed for prote-
ase digestion using Protease 1 reagent (0.5U/ml) for 4 minutes at 37°C and incubated with the
IL36g antisense riboprobes (100 ng/slide) in RiboHybe hybridization buffer (Ventana Medical
Systems, Inc) for 6 hours at 65°C. After 3 stringency washes using 0.1× RiboWash (Ventana
Medical Systems) for 8 minutes each at 75°C, the second fixation step was performed using
RiboFix reagent for 32 minutes at 37°C followed by incubation of Alcaline Phosphatase-labeled
antidigoxigenin antibody (Roche, dilution 1/500) for 32 minutes at 37°C. The signal was de-
tected automatically using the BlueMap NBT/BCIP substrate detection kit (Ventana Medical
Systems, Inc.) for 6 hours at 37°C. Finally, the sections were counterstained with a nuclear fast
red equivalent reagent ISH Red (Ventana Medical Systems, Inc) for 4 minutes
before coverslipping.
FACS analysis of infiltrating cells in infected lungs
After perfusion with 0.02% EDTA-PBS and removal, lung tissue was sliced into 1 to 2 mm3
pieces and was incubated in RPMI 1640 (Gibco, Paisley, Scotland, UK) containing antibiotics
(Penicilline 100 U/ml-Streptomycine 100 μg/ml), 10 mMHepes (Gibco) and collagenase
(150U/ml), DNase (50U/ml; Sigma, St Louis, MO). After 45min of incubation at 37°C, single-
cell suspension was obtained by vigorous pipetting and filtering through 100μm and 20μm.
Cells were washed three times in RPMI 1640 containing 5% BSA and were then stained accord-
ing to antibody manufacturer protocols. Rat anti-mouse CD11b-FITC (clone M1/70),
Gr1-PECy7 (clone RB6-8C5), were from BD Pharmingen (San Diego, CA). Stained cells were
washed twice, fixed with 1% paraformaldehyde (FACS Lysing solution, BD) and analyzed by
flow cytometry on a CANTO II analyser (Becton Dickinson). Data were processed with FlowJo
software (version 7.6.5 for Windows, FlowJo LLC, Ashland, Oregon).
Statistical analysis
Statistical significance was determined with Graph Pad Prism (version 5.04 for Windows,
GraphPad Software, La Jolla, CA). Differences between multiple in vivo groups were analyzed
by one-way non-parametric test (Kruskal-Wallis), before comparing individual groups using a
Mann-Whitney test. Survival curve were compared using Log-rank (Mantel-Cox) test.
IL-36 and Mycobacterial Infection
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Evolution of body weight was compared by using two-way ANOVA for repeated measures, fol-
lowed by Sidak’s multiple comparison test. Values of p 0.05 were considered significant.
Results
IL-36γ expression is enhanced in response to lung inflammation
To determine how IL-36 cytokines are regulated during lung inflammation, mRNA expression
of IL-36 cytokines and IL-36R was first measured 6 h after intratracheal instillation of LPS.
There was a significant increase in pulmonary levels of IL-36γmRNA that remained elevated
at 24 hours in LPS-treated mice as compared to controls instillated with saline (Fig 1). In con-
trast, IL-36α, IL-36β and IL-36R expression was either unchanged or remained undetectable
after LPS exposure (data not shown). IL-36 cytokine and IL-36R mRNA expression was next
determined after intravenous inoculation ofM. bovis BCG infection (5x106 CFU livingM.
bovis BCG Pasteur strain 1173 P2). IL-36γmRNA levels were transiently increased 2 weeks
after infection (P = 0.057), and IL-36g mRNA was present in lung granulomatous lesions after
M. bovis BCG infection, as shown by in situ hybridization (Fig 2A and 2B). Of note,M. bovis
BCG infection barely affected pulmonary IL-36α, IL-36β and IL-36R mRNA levels, although
IL-1β and TNF-α expression was increased (Fig 2A). Thus, lung inflammation was associated
with an upregulation of inflammatory cytokines such as TNF and IL-1 that included IL-36γ.
IL-36R is dispensable for the control of M. bovis BCG infection
Previous results showed that IL-36R signaling is involved in Th1 responses followingM. bovis
BCG infection [5]. Since IL-36γ expression is transiently upregulated and IL-36γ is present in
lung granulomas associated withM. bovis BCG infection, we thus examined whether IL-36R
signaling is involved in host responses againstM. bovis BCG infection. IL-36R KO and WT
mice were inoculated withM. bovis BCG (5 x 106 CFU per mouse, i.v.). Survival and body
weight were not significantly different in WT and IL-36R deficient mice up to 6 months post
Fig 1. Elevated lung IL-36γmRNA levels following LPS instillation. Lung total RNA was extracted 4 h after intra-tracheal instillation of LPS (n = 5 mice) or
saline (n = 5 mice). The results represent the levels of Il36g or Il36rmRNA determined by RT-qPCR normalized toGapdhmRNA. **P<0.01, as assessed by
Mann-Whitney test.
doi:10.1371/journal.pone.0126058.g001
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Fig 2. Kinetic of IL-36 cytokines, IL-36R, IL-1β and TNF-αmRNA expression afterM. bovis BCG infection.mRNA levels of Il36a, Il36b, Il36g, Il36r, Il1b,
and Tnfameasured by RT-qPCR and normalized toGapdhmRNA levels from the lungs of C57BL/6 wild-type mice 2 weeks (n = 4) and 4 weeks (n = 5) after
M. bovis BCG infection. Three naïve mice were included as controls (A). In situ hybridization was performed using a digoxigenin-labeled riboprobe
complementary to Il36gmRNA (B). The micrographs are representative of lungs from one naïve mice (upper panel) and one infected mice 2 weeks afterM.
bovis BCG inoculation (lower panel). *P<0.05, as assessed by Kruskal-Wallis, followed by Mann-Whitney test.
doi:10.1371/journal.pone.0126058.g002
IL-36 and Mycobacterial Infection
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infection (Fig 3A and 3B). Lung inflammatory responses and bacterial clearance were exam-
ined at day 28 postM. bovis BCG injection. Lung weight was increased inM. bovis BCG in-
fected mice as compared to naïve mice, but there was no difference between WT and IL-36R
deficient mice (Fig 3C). Total lung infiltrating inflammatory cell numbers were also enhanced
afterM. bovis BCG infection, the difference with naïve mice reaching statistical significance in
IL-36R KO mice (Fig 3C). Absolute numbers of lung infiltrating CD11b+ myeloid cells, CD4+
and CD8+ T cells were also enhanced followingM. bovis BCG infection (Fig 4), but there was
no significant difference between WT and IL-36R deficient mice. B220 cell numbers were de-
creased with the same magnitude in the two mouse strains in response toM. bovis BCG infec-
tion. There was a significant decrease in free alveolar space in the lungs of IL-36R deficient
mice as compared to WTmice (Fig 5A and 5B), as previously observed [5], suggesting the pres-
ence of enhanced inflammatory responses in the lungs of IL-36R KOmice. However, the pul-
monary bacterial burdens were not significantly different in IL-36R KO and WTmice (Fig 5C).
Furthermore, at 6 months post-infection, the histological findings were no longer different in
IL-36R deficient and WTmice and the presence ofM. bovis BCG was undetectable by CFU
and Ziehl-Neelsen staining in both mouse strains (data not shown). Transcript levels of TNF-
α, IL-6, IL-10, IL-12p40, CXCL1, CXCL2, IFN-γ, GM-CSF, G-CSF, iNOS, T-bet, GATA3,
RORγt were measured in the lungs at day 28 postM. bovis BCG infection. The mRNA levels
were not different between IL-36R deficient and WT mice, with the exception of CXCL1,
CXCL2, and IL-6 that were lower in IL-36R KO than in WTmice (Fig 6A). The serum levels of
CXCL1 that peaked 2 weeks post-M. bovis BCG infection were significantly lower in IL-36R
KO than in WTmice at this time-point (Fig 6B). Thus, the transiently increased lung inflam-
mation inM. bovis BCG infected IL-36R deficient mice did not translate in an increase in in-
flammatory cytokine expression, and was associated with a decrease in CXCL1 expression.
Limited contribution of IL-36R, compared to IL-1RI and TNF-α pathways
in the control of M. tuberculosis infection
The expression levels of IL-36α, β, γ, IL-1β, TNF-α and IFN-γmRNA were next determined in
the lungs of WT and TNF-α deficient mice at different time-points following aerogenic infec-
tion withM. tuberculosis. IL-36γ and IL-36R mRNA levels remained unchanged up to 27 days
afterM. tuberculosis infection in WTmice. In contrast, the transcript levels of IL-1β, TNF-α,
and IFN-γ were significantly increased at day 14 and were further upregulated at day 21 and 28
(Fig 7). In the highly susceptible,M. tuberculosis infected TNF-α deficient mice, the mRNA lev-
els of IL-1β and IFN-γ were even higher than in WT mice. Furthermore, there was a significant
increase of IL-36γmRNA levels in TNF-α deficient mice infected withM. tuberculosis.
To assess the contribution of the IL-36 pathway to host responses againstM. tuberculosis in-
fection, WT and IL-36R deficient mice were infected by intra-nasal instillation ofM. tuberculo-
sis. Mice deficient for IL-1RI and TNF-α were included as controls since both mouse strains
have previously been reported to exhibit a reduced control of acuteM. tuberculosis infection as-
sociated with enhanced lethality. IL-36R deficient mice had a similar evolution of body weight
and survival as compared to WT mice up to 4 months afterM. tuberculosis infection. In con-
trast, 100% of TNF-αmice died or had to be sacrificed within one month post infection and
IL-1R1 deficient mice exhibited an intermediate susceptibility with a 50% survival during the 4
months follow-up period (P = 0.0455) (Fig 8A and 8B). Consistent with these findings, lung
weights and bacterial loads were significantly increased in TNF-α deficient mice as compared
to WT mice (P<0.0001) (Fig 8C). In addition, macroscopic and histological examination
showed that the lungs of TNF-a mice exhibited massive inflammatory responses after one
month of infection with reduced free alveolar space (Fig 9) and enhanced bacterial load as
IL-36 and Mycobacterial Infection
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Fig 3. Role of IL-36R signaling inM. bovisBCG infection.Wild-type and IL-36R deficient mice were
inoculated intravenously withM. bovis BCG (n = 12 per group). Six mice from each genotype were sacrificed
at 28 days and the other mice were followed for up to 180 days. The percentage of survival (A) and evolution
of body weight (B) for WT and IL-36R deficient mice are depicted. (C) Total lung weight and absolute lung cell
numbers at 28 days after infection are represented in left and right panels, respectively. No significant
differences were observed betweenWT and IL-36R KOmice, as assessed by log-rank (Mantel-Cox) test (A)
or two-way ANOVA for repeated measures, followed by Sidak’s multiple comparison test (B). *P<0.05, as
assessed by Kruskal-Wallis, followed by Mann-Whitney test (C). Black and grey symbols represent WT and
IL-36R deficient mice, respectively.
doi:10.1371/journal.pone.0126058.g003
IL-36 and Mycobacterial Infection
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assessed by Ziehl-Neelsen staining (Fig 9). Bacterial burden was significantly increased in IL-
1R1 deficient mice as compared to WT mice at 1 month (P = 0.0091) and 4 months
(P = 0.0193) post-infection (Fig 8C and 8D). There was no difference regarding lung weight,
bacterial load or histopathological findings between IL-36 KO and WTmice at 1 or 4 months
post-infection (Figs 8 and 9). Lung inflammatory response was further analyzed by assessing
the level of the typical pro-inflammatory, Th1 cytokine IFN-γ and of the chemokine CXCL1
(Fig 10). In line with their increased lung inflammation, lung IFN-γ levels of were significantly
increased in TNF-α deficient mice at 1 month post infection as compared to WT mice, as well
as in IL-1RI deficient as compared to WTmice at 4 months, while IL-36R deficient mice
Fig 4. Changes in lung cell populations followingM. bovisBCG inoculation. Lung cells were isolated from 3 naiveWT and IL-36R deficient mice, and
from 6WT and 6 IL-36R deficient mice 4 weeks after intravenousM. bovis BCG inoculation. The results represent CD11b+, CD4+, CD8+, and B220+ cell
numbers as assessed by flow cytometric analysis. *P<0.05, as assessed by Kruskal-Wallis, followed by Mann-Whitney test.
doi:10.1371/journal.pone.0126058.g004
IL-36 and Mycobacterial Infection
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Fig 5. Histopathology and bacterial loads in wild-type and IL-36R deficient mice.Hematoxylin eosin staining of lung sections 4 weeks afterM. bovis
BCG infection of WT (left panels) and IL-36R deficient (right panels) mice (original magnifications X2, upper panel, and X40, lower panel) (A). Determination
of free alveolar space on lung sections. Data are represented as the mean ± SD of percentage of lung lesion free/total lung tissue in 5 mice per group with 1
or 2 lobes analyzed per mouse (B). Lung bacterial loads at 4 weeks post-infection are represented as CFU per lung (n = 6 mice per group) (C). **P<0.01 as
assessed by MannWhitney test.
doi:10.1371/journal.pone.0126058.g005
IL-36 and Mycobacterial Infection
PLOS ONE | DOI:10.1371/journal.pone.0126058 May 7, 2015 11 / 21
exhibited IFN-γ levels similar to WT controls. The levels of CXCL1 were increased in TNF-α
deficient mice, although this did not reach significance, but were significantly decreased in IL-
1RI deficient mice at 1 and 4 months post infection. There was no difference in the lung levels
of CXCL1 in IL-36R deficient and WTmice at 1 and 4 months post-infection. Finally, flow
cytometric analysis of lung infiltrating cells showed similar numbers of granulocytic and
monocytic CD11b+ Gr1+ and CD11b+ Gr1- cells in IL-36R deficient and WT mice, as well as
similar numbers of CD3+ T cells at 1 month after infection (Fig 11). Therefore, IL-36R defi-
ciency did not impair the control ofM. tuberculosis infection as did the absence of TNF-α or
IL-1R1 signalling.
Fig 6. CXCL1 expression in response toM. bovis infection in IL-36R deficient and wild-typemice. A. Total RNA was prepared from the lungs of naïve
(open symbols) andM. bovis BCG infected (closed symbols) WT (black circles) and IL-36R deficient (grey squares) mice. The results representCxcl1, Cxcl2,
and Il6mRNA levels determined by RT-qPCR normalized toGapdhmRNA levels in individual mice. *P<0.05, as assessed by Kruskal-Wallis, followed by
Mann-Whitney test. B. Serum levels of Cxcl1 were measured by ELISA in WT (black symbols) and IL-36R deficient (grey symbols) mice. The results
represent means ± SEM of 6 mice per group. Two-way ANOVA for repeated measures, followed by Sidak’s multiple comparison test was used to compare
IL-36R deficient andWTmice. ***P<0.001 only at week 2.
doi:10.1371/journal.pone.0126058.g006
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Fig 7. Kinetics of pulmonary cytokine expression afterM. tuberculosis infection. Total RNA was
prepared from the lungs of naïveWT (black symbols) and TNF-α deficient mice (grey symbols) and at days 7,
14, 21 and 27 afterM. tuberculosis infection in WT (black symbols) and at day 27 in TNF-α deficient mice
(grey symbols). The results represent the levels of Il36g, Il36r, Tnfa, Il1b, and IfngmRNA determined by RT-
qPCR normalized to L32mRNA (n = 5 per group). *P<0.05, **P<0.01, as assessed by Kruskal-Wallis,
followed by Mann-Whitney test (C).
doi:10.1371/journal.pone.0126058.g007
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Fig 8. IL-36R is dispensable to control acuteM. tuberculosis infection.Mice deficient for IL-36R, IL-1R1
or TNF-α, andWTmice were exposed to an aerogenic dose ofM. tuberculosis H37Rv and monitored for
survival (A) and body weight. The results represent mean body weight ± SEM values of 8–14 mice per group,
pooled from 2 independent experiments. Lung weight (left panels) and bacterial loads (right panels) were
determined in TNF-α deficient, IL-36R deficient, IL-1R1 deficient, andWTmice at 1 month (C) and 4 months
(D) post infection. Results are expressed as individual values and mean (n = 4–9 for lung weight, n = 3–9 for
CFU) from 1 experiment at 1 month and (n = 5–12 for lung weight, n = 5–10 for CFU) from 2 experiments at 4
months. *P<0.05, **P<0.01, ***P<0.001 as compared to the wild-type controls (assessed by Kruskal-
Wallis, followed by Mann-Whitney test).
doi:10.1371/journal.pone.0126058.g008
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Fig 9. Controlled lung pathology afterM. tuberculosis infection in the absence of IL-36R pathway.Macroscopic lung lesions of IL-36R deficient, IL-
1R1 deficient, TNF-α deficient, andWTmice at 1 month, and of IL-36R deficient andWTmice at 4 months postM. tuberculosis infection (A). Histological
studies were performed at 1 month in IL-36R deficient, IL-1R1 deficient, TNF-α deficient, andWTmice (B), and at 4 months in IL-36R deficient andWTmice
(C). Representative lung H&E (1x and 40x magnifications) and Ziehl-Neelsen (60x magnification) staining at 1 and 4 months postM. tuberculosis infection.
Free alveolar space quantification is represented as the mean ± SD of percentage lung lesion free/total lung tissue in 4–7 mice per group with 1–2 lobes
analyzed per mouse (D). Statistical analysis was one-way ANOVA, no statistically significantly differences were observed between animal groups.
doi:10.1371/journal.pone.0126058.g009
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Discussion
We show here that IL-36γmRNA expression is enhanced during acute lung inflammation in-
duced by intratracheal LPS instillation orM. bovis BCG systemic infection in WTmice and
after aerogenicM. tuberculosis infection of highly susceptible, TNF-α deficient mice. To under-
stand whether IL-36γ expression represents a host defense mechanism essential to fight the in-
fection, or is rather a consequence of the enhanced inflammatory response induced by the
uncontrolled infection, we addressed the relevance of IL-36 pathway in controlling lung in-
flammation and infection by mycobacteria. IL-36R deficient mice had transiently increased
lung pathology and reduced lung chemokine CXCL1 production followingM. bovis BCG infec-
tion, but without long term consequences on bacterial control. Indeed, while TNF-α KOmice
succumbed after acuteM. tuberculosis infection with high bacterial loads and severe inflamma-
tory responses and IL-1R1 KO mice exhibited an intermediate phenotype, the survival, bacteri-
al clearance, and inflammatory responses were similar in IL-36R deficient and WT mice.
Taken together, these results indicate that IL-36R signaling has limited contribution on host re-
sponses to mycobacterial infections.
Like other IL-1 family members, IL-36 is produced by stimulated innate immune cells, in-
cluding macrophages and DC, and may thus contribute to host defense against pathogens.
Human peripheral blood mononuclear cells produce IL-36γ and IL-36Ra in response to Asper-
gillus fumigatus infection, and the addition of IL-36Ra inhibits the production of IL-17 and
IFN-γ, suggesting that IL-36 is involved in the production of these cytokines by PBMC in re-
sponse to Aspergillus fumigatus infection [32]. Human monocyte-derived DC (MDC) and po-
larized M1 macrophages produce IL-36γ in response to IL-1, TNF-α, and IFN-γ, an expression
dependent on t-bet, the transcription factor T-box expressed in T cells [33]. Mouse bone mar-
row-derived DC (BMDC) express IL-36γ and IL-36α either constitutively or in response to var-
ious stimulations [2]. Consistent with these in vitro findings we show here the presence of IL-
36γ in granulomatous lung lesions fromM. bovis BCG infected mice.
IL-36R is expressed by BMDC and IL-36 stimulates the production of several cytokines and
chemokines, as well as the expression of MHC class 2 molecules and co-stimulatory receptors
Fig 10. Lung IFN-γ and Cxcl-1 levels inM. tuberculosis infection. The levels of IFN-γ and Cxcl-1 protein were determined in lung homogenates 1 month
post aerogenicM. tuberculosis infection in TNF-α deficient, IL-36R deficient, IL-1R1 deficient, and wild-type mice, and 4 months post-infection in IL-36R
deficient andWTmice. Results are expressed as mean +/- SEM of n = 3–9 from 1 experiment at 1 month, n = 5–10 from 2 experiments at 4 months. P<0.05
*; P<0.01 ** as compared to theWTmice.
doi:10.1371/journal.pone.0126058.g010
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[2]. Similarly, IL-36 stimulates the expression of cytokines and induces MDC maturation with
enhanced MHC class 2, CD83 and CD86 expression [3], [4]. IL-36R is also expressed by CD4
+ T cells, in particular naïve CD4+ T cells, and IL-36 induces Th1 responses in vitro and in
vivo [5]. The stimulatory effects of IL-36 on Th1 polarization are dependent on the release of
IL-12 by DC and the production of IL-2 by CD4+ T cells, which in turn induces IL-12Rβ2 ex-
pression [5]. These findings suggested that IL-36 could play an important role in host defense
against mycobacterial infections. However, we show here that host responses involved inM.
Fig 11. Unaffected lung inflammatory cell infiltration in the absence of IL-36R pathway afterM. tuberculosis infection. Infiltrating cells in the lungs of
IL-36R deficient (right panels) and wild-type mice (left panels) were isolated on day 28 afterM. tuberculosis H37Rv infection, and analyzed by flow cytometry
for the expression of CD11b, Gr1 (Ly6G/6C) and CD3. Gating strategy and representative dot blots are shown (A). Results expressed as the absolute
number of CD11b+Gr1high, CD11b+Gr1low and Gr1low CD3ε+ cells per lung are from 3 individual mice with mean values as horizontal bars (B).
doi:10.1371/journal.pone.0126058.g011
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bovis BCG andM. tuberculosis infection containment and survival were largely independent of
IL-36R signaling. Consistent with these results, IL-36R signaling is also dispensable for the con-
trol of footpad infection with Leishmania guyanensis, another infectious model in which Th1
responses play a critical role for parasitic clearance (Lamacchia, Gabay et al, unpublished data).
Recent data indicate that various inflammatory stimulants also induce IL-36 production by
bronchial epithelial cells, including TNF-α, IL-1β and IL-17, as well as cigarette smoke conden-
sate [34], [35]. Production of IL-36γ by bronchial epithelial cells is also markedly stimulated by
infectious agents, including Pseudomonas aeruginosa [36] and rhinovirus, with higher rhinovi-
rus-induced IL-36γ in epithelial cells from asthmatic patients [37]. InM. bovis BCG infected
mice the levels of CXCL1, CXCL2, and IL-6 were transiently lower in IL-36R KO as compared
to WT mice, with no consequence on the severity of lung infection and survival. Similarly,
there was no difference in lung inflammatory responses following aerogenicM. tuberculosis in-
fection in IL-36R KO andWT mice. Furthermore, although IL-36γ production was enhanced
in response to intratracheal LPS instillation, the severity of inflammatory responses, as assessed
by cellular composition and cytokine levels in bronchoalveolar lavages, was unaffected by IL-
36R deficiency (Woldt, Gabay et al, unpublished results).
Regarding other IL-1 family cytokine pathways, mice deficient in IL-1α/β and IL-1R1 sig-
naling exhibit enhanced bacterial loads and reduced survival in response toM. tuberculosis in-
fection, although adaptive responses are essentially unaltered [38], [20], [23], [24]. A
mechanism through which IL-1 may controlM. tuberculosis infection has recently been pro-
posed, namely IL-1 induced release of prostaglandin E2, which exerts an inhibitory effect on
type I IFN production, leading to better bacterial containment [39]. In our study, the pheno-
type of IL-1R1 KO mice was less severe than in TNF-α deficient mice. This finding is in accor-
dance with the predominant role of TNF-α in the control of latent and primary tuberculosis
infection in humans [13], [14], [15], [16], and mice [24].
Several data obtained in mice and humans indicate that IL-36R signaling is involved in the
pathogenesis of psoriasis. Transgenic mice overexpressing IL-36α exhibited transient skin
changes reminiscent of psoriasis. This phenotype was abrogated when transgenic mice were
crossed with IL-36R or IL-1RAcP deficient mice, but strongly exacerbated when IL-36α trans-
genic mice were crossed with IL-36Ra deficient mice [26]. Treatment of SCID mice engrafted
with human psoriasis skin with a monoclonal anti-human IL-36R neutralizing antibody led to
substantial normalization of engrafted skin pathology [40]. Imiquimod, a TLR7 agonist, can in-
duce psoriasis-like lesions in human and mice. This effect is almost completely dependent
upon IL-36R signaling [41]. Finally one of the most compelling evidence regarding a role of IL-
36R signaling in psoriasis is the presence of a variety of IL36RN gene mutations leading to
non-functional IL-36Ra in some patients with generalized pustular psoriasis (reviewed in [25]).
In the search of new therapeutic strategies limiting the risk of tuberculosis reactivation, our
previous studies showed that targeting selectively soluble TNF but sparing membrane TNF by
Dominant Negative-TNF inhibitor molecules did not compromise immune responses to both
M. bovis BCG andM. tuberculosis infections in contrast to other TNF neutralizing molecules
[42], while efficiently protecting mice against acute inflammatory reactions [30]. Here we show
that the host response toM. tuberculosis was preserved in the complete absence of IL-36R sig-
naling. Our data suggest that targeting IL-36R signaling, for example in the context of general-
ized pustular psoriasis or other forms of psoriasis [43] may be considered as a new, safe
therapeutic strategy unlikely to compromise host immunity to mycobacteria, thereby reducing
the risk of tuberculosis reactivation that is associated with TNF antagonists.
In conclusion, despite in vitro and in vivo findings indicating that IL-36R signaling stimu-
lates Th1 responses, and that IL-36γ is over-expressed in the inflamed lung, our results show
that the IL-36 pathway is dispensable for the control of mycobacterial infection. This suggests
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that neutralizing IL-36 may allow therapeutic interventions for severe inflammatory indica-
tions while sparing host control of tuberculosis.
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